New iPad Winner:
Lecil Guerzon from Middletown, CT

$100 Amazon Gift Card Winner:
Amanda Jacobs from Kinston, NC

• Changed their practice after attending ONS:Edge programming.
• Shared what they learned with their colleagues.
• Prefer ONS:Edge non-CNE programming over similar programs from other hosts.

Download the PDF below to learn more!

Please join ONS:Edge and Omnicare Specialty Care Group Advanced Care Scripts for a presentation and meal. The program will teach you how specialty pharmacy services can ensure that all patients have access to quality care and affordable medications. Using case studies and examples from practice, the speaker will discuss:

• Coverage and reimbursement support
• Affordability solutions
• Clinical support
• Compliance and adherence through active touch points and product packaging
• Patient education and nursing resources

This program has been planned and developed in collaboration by Omnicare Specialty Care Group and ONS:Edge, Inc., a subsidiary of the Oncology Nursing Society, and is sponsored by Omnicare Specialty Care Group.

Seating for the Program

Seating for people pre-registered for this program will begin 30 minutes prior to program start time. Open seating will be made available to onsite registrants 10 minutes prior to the start of the program. Seats not occupied at that time will be forfeited to on-site registrants.

NOTE: By providing your e-mail or fax, you are granting permission to ONS, its subsidiaries, and Omnicare Specialty Care Group to communicate with you via e-mail or fax. ONS and its affiliates will not share e-mail or fax information with outside entities.

Program Objectives: 

• Learn about the pathology and symptoms of myelofibrosis (MF)
• Learn about diagnosing and treating patients with MF
• Discuss resources for you and your patients with MF

Unless otherwise noted, program registration is from 6:00-6:30pm
Programs begin promptly at 6:30pm

More event details to come!

No continuing nursing education (CNE) contact hours will be awarded.

Seating for the Program

RSVP is not a guarantee of admission. Seating for people pre-registered for this program will begin 30 minutes prior to program start time. Open seating begins 10 minutes before the start of the program. “Open seating” means that seats not occupied at that time will be forfeited to on-site registrants. Doors close at the posted program time or when all seats are filled, whichever comes first.

Xpedite allows health care professionals to order printed XELODA materials for delivery to their practice. These materials provide important information and help educate patients about XELODA therapy.

EXCLUSIVE OFFER Place an order for Selections From Difficult Conversations: Nurses Share Lessons from Cancer’s Frontline to get real stories from real nurses.

In the book, editor Kathy LaTour gives a glimpse into the difficult but essential discussions oncology nurses have with their cancer patients. With each topic explored, LaTour offers discussion strategies and resources to assist in approaching the toughest conversations.

Help support your patients by placing an order today:

Please see full Prescribing Information, including Boxed WARNING, for additional Important Safety Information.

Indications

XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent XELODA in the adjuvant treatment of Dukes’ C colon cancer.

XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage.

XELODA monotherapy is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m² of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.

XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

Boxed WARNING and Additional Important Safety Information

Boxed Warning
Warfarin Interaction – Coagulopathy

• Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly.
• A clinically important XELODA-Warfarin drug interaction was demonstrated in a clinical pharmacology trial.
• Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
• Postmarketing reports have shown clinically significant increases in prothrombin time (PT) and INR have been observed in patients who were stabilized on anticoagulants at the time XELODA was introduced. These events occurred within several days and up to several months after initiating XELODA therapy, and in a few cases within 1 month after stopping XELODA. These events occurred in patients with and without liver metastases.
• Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.
• XELODA is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency, or severe renal impairment. XELODA is also contraindicated in patients with known hypersensitivity to capecitabine or to any of its components or to 5-fluorouracil.
• Additional serious adverse reactions include diarrhea, cardiotoxicity, hand-and-foot syndrome, and hyperbilirubinemia. XELODA can cause fetal harm. Advise women of the potential risk to the fetus. Do not treat patients with neutrophil counts <1.5 x 10⁹/L or thrombocyte counts <100 x 10⁹/L.
• The most common adverse reactions (≥30%) reported were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, including serious adverse reactions, have been reported.

XELODA is a registered trademark of Hoffmann-La Roche Inc.
©2012 Genentech USA, Inc. All rights reserved.   08/12   XEL0001269600

Additionally, it is important that all healthcare professionals attending promotional programs check their employer’s policies regarding attendance. Many research and teaching hospitals post policies online and employees should contact their human resources departments for information.

Download the PDF below to learn more!

Nurses frequently express frustration with the declining availability of CNE and its rising cost. Their concerns have led ONS:Edge to ask whether oncology nurses would willingly participate in free online education that does not offer CNE. The results of a recent investigation suggest a resounding, "Yes!"

Download the PDF below to learn more!

Oncology nurses have an important role in the management of patients with cancer. This interactive program will provide you with clinical information and resources about anemia, neutropenia, and bone health. Join us for an educational presentation and meal to learn about oncology nursing-specific resources that are available now and will assist you in your daily practice. The faculty will:

• Identify a plan and resources you can use to incorporate comprehensive risk assessment into your patient care.
• Discuss the symptoms and impact of anemia on patients with cancer and oncology nursing resources that are available to you.
• Review the critical issue of skeletal-related events in patients with cancer and learn about resources that are available for your practice.

This program has been planned and developed in collaboration by Amgen Inc. and ONS:Edge, Inc., a subsidiary of the Oncology Nursing Society, and is sponsored by Amgen Inc.

Seating for the Program

Seating for people pre-registered for this program will begin 30 minutes prior to program start time. Open seating will be made available to onsite registrants 10 minutes prior to the start of the program. Seats not occupied at that time will be forfeited to on-site registrants.

NOTE: By providing your e-mail or fax, you are granting permission to ONS, its subsidiaries, and Amgen to communicate with you via e-mail or fax. ONS and its affiliates will not share e-mail or fax information with outside entities.

Healthcare practitioners and providers licensed in Massachusetts, Vermont, and Minnesota: To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Massachusetts, Vermont, and Minnesota; and (2) individuals employed by prescribers in Massachusetts and Vermont who support the provision of health care. We appreciate your understanding and support.

No continuing nursing education (CNE) contact hours will be awarded.

More dates and locations to be announced soon!

In preparation for its session at the 2012 ONS Leadership Weekend entitled, “Why Can’t I Attend that Session?” ONS:Edge conducted a survey of ONS member leaders to evaluate their knowledge about current laws, rules, and regulations that affect oncology nurse participation in pharmaceutical promotional events or activities. Examples include live dinner events (that do not offer CNE), advisory boards, consulting arrangements, and speaker bureaus.

618 ONS chapter leaders (presidents, presidents-elect, and program chairs) received the survey. 234 responses were received, for a 38% response rate – unusually high. Clearly, ONS:Edge has hit upon an area of real interest and concern to ONS leadership.

The responses demonstrated that nurses’ knowledge about rules and regulations regarding relationships with pharmaceutical companies and participation in promotional activities is somewhat limited.

Download the PDF below to learn more!

Order a free copy of a White Paper which reviews current practice in managing advanced NSCLC and puts VeriStrat in its appropriate context for oncology nurses. Biodesix and ONS:Edge are pleased to provide, ONS:Edge White Paper: Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer.

Please be advised the VeriStrat Support Hotline telephone number is 1-866-432-5930